Dai-ichi Karkaria announces conclusion of agreement with GVK Bio & Inogent

Pares stake in Inogent

Dai-ichi Karkaria announced that pursuant to the Call Option under the Joint Venture and Shareholders Agreement among GVK Biosciences (GVK Bio), Dai-Ichi Karkaria (the Company) and Inogent Laboratories (Inogent), dated 14 October 2005, GVK Bio has acquired balance 9,87,500 equity shares (6.12% of voting powers) of Inogent from the Company on 11 July 2014, at a consideration aggregating to Rs. 8.97 crore.

Accordingly, the shareholding of the Company in Inogent after the acquisition will be NIL and the Agreement shall be treated as concluded.

Powered by Capital Market - Live News